MS launches securitisation deal

Investment bank Morgan Stanley has launched a $250m (£154m) securitisation deal for US biotech firm, Vertex Pharmaceuticals, for a drug which is still in development. The deal signals that life is returning to intellectual property right securitisation and that investors are gaining appetite for deals that many thought would be unsavoury for a long time to come.